Module 2: Current and emerging treatments in nmHSPC after BCR
Primary Audience:
This activity is intended to meet the educational needs of urologists, medical oncologists and radiation oncologists involved in the care of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC).
This module will cover the current and emerging treatments for non-metastatic hormone-sensitive prostate cancer (nmHSPC) following biochemical relapse (BCR).
Catherine Handy Marshall, MD, MPH
Assistant Professor of Oncology
Internal Medicine, Oncology
Johns Hopkins School of Medicine
Baltimore, MD
Dr. Catherine Marshall is an Assistant Professor in the Department of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include internal medicine and oncology.
She received her M.D. and M.P.H. from Johns Hopkins, where she also completed her residency and an oncology fellowship.
1.
Understand the various treatment options and their indications, benefits, and risks for patients with nmHSPC.
